

Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

Bluebox Precision Medicine Fund (the "Fund") A sub-fund of BlueBox Funds (the "SICAV").

A (USD) acc., ISIN: LU2519372499

The Fund is managed by Carne Global Fund Managers (Luxembourg) S.A. (The "Manager")

Objectives and Investment Policy

The main objective of the Fund is to seek to maximise total return. The Fund invests globally with at least 85% of its total assets in the equity securities of companies whose predominant economic activity is in the pharmaceuticals, biotechnology and life science sectors.

The remaining 15% of the total assets of the BlueBox Precision Medicine Fund may be invested in equity securities of companies or issuers of any size in any sector of the economy globally and whose predominant economic activity is not in the pharmaceuticals, biotechnology and life science sectors.

When the Management Company believes it is in the best interests of the Shareholders to do so, the Management Company may, for cash management purposes, for the preservation of capital, for diversification and liquidity management purposes as well as for short-term defensive purposes invest up to 100% of the total assets of the BlueBox Precision Medicine Fund in cash and cash equivalents, bank deposits, Money Market Instruments, money market UCITS and Other UCIs or other liquid assets. During these periods, the BlueBox Precision Medicine Fund may not achieve its objective.

The overall investment strategy of the BlueBox Precision Medicine Fund is to seek out companies that will create value for the Shareholders from precision medicine: the multi-year trend of increasingly precise and targeted drug development in the pharmaceutical and biotechnology industries.

The BlueBox Precision Medicine Fund will typically hold 25-45 positions. The holding periods are expected to be generally long (multiple years) and turnover low, although at times the BlueBox Precision Medicine Fund may utilise shorter holding periods if value is realised more quickly or unexpected events occur. The geographic focus of the strategy is global. The sector focus is predominantly pharmaceuticals, biotechnology and life science, however the BlueBox Precision Medicine Fund may also acquire shares in companies classified in other sectors with a strong pharmaceutical, biotechnology or life science element to their business.

Holdings will be primarily of publicly listed companies, typically with a market capitalisation of about \$1bn or more, but the BlueBox Precision Medicine Fund will take part in initial public offerings (where the market cap may be significantly below \$1bn at listing) and it may occasionally invest in private companies where an initial public offering is strongly expected to follow within 18 months or so. The BlueBox Precision Medicine Fund may not acquire shares carrying voting rights which should enable it to exercise significant influence over the management of an issuing body.

The Fund promotes environmental, social and governance (ESG) characteristics and is thus classified as a financial product falling within the scope of Article 8 of the SFDR. For details of ESG approach, please refer to www.blueboxfunds.com.

Investments in a currency other than the Reference Currency of the BlueBox Precision Medicine Fund may be hedged against the Reference Currency of the BlueBox Precision Medicine Fund. The BlueBox Precision Medicine Fund will not invest in FDIs, nor enter into any securities financing transaction within the meaning of the SFT Regulations.

Should the BlueBox Precision Medicine Fund wish at a later stage to enter into any of these transactions, the Prospectus will be updated accordingly. It is currently not contemplated for the BlueBox Precision Medicine Fund to invest in Russian equities or equity related securities.

Purchase and sale of shares in the Fund can be made on each Business Day.

The Fund is active and managed without any reference to a benchmark. The Management Company has discretion over the composition of its portfolio subject to this objective and investment policy.

Recommendation: this Fund may not be appropriate for investors who plan to withdraw their money within five years.

The Fund does not intend to declare or make distributions.

Risk and Reward Profile



Historical data may not be a reliable indication for the future.

The risk category shown is not guaranteed and may shift over time.

The lowest category does not mean 'risk free'.

This Fund is in category 6 since the share price has a high volatility, therefore the risk of loss as well as the expected reward can be high.

The following risks may not be fully captured by the risk and reward indicator:

Equity Risk: The risk that investments depreciate because of stock market dynamics.

Market Risk: The Fund's assets may decrease because of sovereign acts and political transformation, which may also influence free trade of currency. In addition, risks may arise because of restricted information possibilities in addition to less stringent supervision and control of certain markets. The performance of these markets may be subject to significant volatility.

The concentration of the Fund on a given country implies the risk that the events concerning the given country may significantly and negatively affect the value of the whole portfolio of the Fund.

A complete description of risk factors is set out in the Prospectus in the section entitled 'Risk Factors Annex'.

Charges

One-off charges taken before or after you invest

Entry charge	5.00%
Exit charge	None

These are the maximum charges that we might take out of your money before it is invested and before we pay out the sale proceeds of your investment. In some cases, you might pay less, and you should speak to your financial adviser about this.

Charges taken from the Fund over a year

Ongoing charges	2.79%
-----------------	-------

Charges taken from the Fund under certain specific conditions

Performance fee	None
-----------------	------

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

The entry and exit charges shown are maximum figures. In some cases you might pay less. Please refer to your financial advisor or the distributor for the actual charges.

The ongoing charges figure is based on expenses for the year ending 31 December 2024.


This figure may vary from year to year. It excludes:

- Performance Fees.
- Portfolio transaction costs, except in the case of an entry/exit charge paid by the Fund when buying or selling units in another Fund.

For more information on charges, please see the "Fees, charges and expenses" section of the Prospectus.

Past Performance

■ A (USD) acc.



- Past returns are not a reliable indicator or guide of future returns.
- Past performance has been calculated in USD.
- The returns in this table include all fees and expenses and show percentage year- on- year changes in the value of the Fund.
- The Fund was launched as a UCITS on 28 February 2023. This Share Class was launched on 14 June 2023.

Practical Information

This Key Investor Information Document (KIID) is specific to this share class. Other Share Classes are available for this Fund as described in the Fund's prospectus.

Depository: The Fund's assets are held with Northern Trust Global Services SE and are segregated from the assets of other sub- funds of the Company. The assets of the Fund cannot be used to pay the debts of other sub- funds of the Company.

Taxation: The Fund is subject to taxation legislation in Luxembourg, which may have an impact on your personal tax position as an investor in the Fund.

Liability: Carne Global Fund Managers (Luxembourg) S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus for the Fund.

Specific information: You may convert shares in the Fund for shares in other Sub- Funds. Further information and provisions are in the Prospectus.

Remuneration Policy: A paper copy of the up- to- date remuneration policy of the Management Company, including, but not limited to, a description of how remuneration and benefits are calculated, and the persons responsible for awarding the remuneration and benefits, is available free of charge upon request. A detailed description of the policy is also available at <https://www.carnegroup.com/policies>.

Further information and price availability: Further information about the Company (including the current Prospectus and most recent annual report) is available in English, and information about the Fund and other share classes (including the latest prices of shares and translated versions of this document), are available free of charge from the registered office of the Management Company, or on www.blueboxfunds.com.

This Fund is authorised in Luxembourg and supervised by the Commission de Surveillance du Secteur Financier.

The Management Company is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier.

This Key Investor Information Document is accurate as at 19 February 2025.